IND Strategy & Submission
Regulatory Advisory
Regulatory strategy that keeps pace with global standards.
Regulatory choices made early — what data, when, with what study design — shape the pace of the whole program. ACRO provides the regulatory authority regulatory advisory grounded in the biostatistical and clinical intelligence behind every submission.
We work as an advisory partner: sponsors retain or engage specialist regulatory firms for full dossier compilation, while ACRO contributes the methodological substance — design rationale, statistical justification, dose strategy — that makes a submission scientifically defensible.
Related reading
Why it matters
Drug development today operates inside a global standards framework — ICH M12 (effective 2024) sets new expectations for drug–drug interaction studies, and ICH E-series guidelines anchor regulatory review practice across regions. Strong regulatory submissions reflect both local procedural requirements and international scientific expectations — and they stand or fall on the methodological coherence behind them.
What we offer
- Regulatory pathway memo — pathway sequencing and scientific rationale
- Pre-submission scientific advice planning
- Statistical and methodological sections for IND submissions
- Dose justification and exposure–response narratives
- Response preparation for regulatory queries
How we work
We focus on the methodological substance — design, statistics, dose justification — that drives regulatory dialogue. Sponsors needing full dossier compilation or multi-region submissions engage specialist regulatory firms; ACRO contributes the scientific arguments and statistical work that strengthen those submissions.
Related services
- PK/PD Modeling — population PK and exposure–response modeling support dose strategy
- Protocol Development — protocol drafted with target regulatory pathway
- Biostatistics — design and analysis methodology behind submissions